刁星星 - 中国科学院上海药物研究所 -

个人简介

教育经历 2005.9-2009.6，武汉大学，药学，理学学士 2009.9-2014.7，中国科学院大学，药物分析，理学博士工作经历 2014.7-2016.6，美国国立卫生研究院国立滥用药物研究所，博士后 2016.6-2018.8，美国XenoBiotic Laboratories，科学家I/II 2018.8-2019.2，美国Celgene公司，科学家II 2019.2-至今，中国科学院上海药物研究所，研究员，课题组长

研究领域

药物代谢、药物不良反应机理、新代谢途径、反常药动学、药物代谢新技术低辐射能量放射性同位素[14C]/[3H]标记技术在新药DMPK中的应用

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1.Diao X, Huestis MA (2019). New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites. Frontiers in Chemistry, 7:109 2.Diao X, Carlier J, Zhu M, Huestis MA (2018). Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry. Forensic Toxicol, 36:304-312 3.Carlier J#, Diao X#, Huestis MA (2018). Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high-resolution mass spectrometry detection. J Pharm Biomed Anal, 157: 27-35 4.Diao X#, Carlier J#, Zhu M, Huestis MA (2017). Human hepatocyte metabolism of novel synthetic cannabinoids MN-18 and its 5-fluoro analog 5F-MN-18. Clin Chem, 63: 1753-1763 5.Diao X#, Carlier J#, Scheidweiler KB, Huestis MA (2017). In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry. Forensic Toxicol, 35: 252-262 6.Diao X, Huestis MA (2017). Approaches, challenges and advances in metabolism of new synthetic cannabinoids and identification of optimal urinary marker metabolites. Clin Pharmacol Ther, 101: 239-253 7.Carlier J#, Diao X#, Sempio C, Baumann MH, Huestis MA (2017) Identification of new synthetic cannabinoid ADB-CHMINACA (MAB-CHMINACA) metabolites in human hepatocytes. AAPS J, 19: 568-577 8.Diao X, Carlier J, Zhu M, Pang S, Kronstrand R, Scheidweiler KB, Huestis MA (2017). In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic Toxicol, 35: 20-32 9.Diao X, Scheidweiler KB, Wohlfarth A, Zhu M, Pang S, Huestis MA (2016). Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes. Forensic Toxicol, 34: 256-267 (IF = 3.7) 10.Diao X, Scheidweiler KB, Wohlfarth A, Pang S, Kronstrand R, Huestis MA (2016). In vitro and in vivo human metabolism of synthetic cannabinoids FDU-PB-22 and FUB-PB-22. AAPS J, 18: 455-464 11.Diao X, Wohlfarth A, Pang S, Scheidweiler KB, Huestis MA (2016). High-resolution mass spectrometry for characterizing the metabolism of synthetic cannabinoids THJ-018 and its 5-fluoro analog THJ-2201 after incubation in human hepatocytes. Clin Chem, 62: 157-169 12.Diao X, Zhong K, Li X, Zhong D, Chen X (2015). Isomer-selective distribution of 3-n-butylphthalide (NBP) hydroxylated metabolites, 3-OH-NBP and 10-OH-NBP, across the rat blood-brain barrier. Acta Pharmacol Sin, 36: 1520-1527 13.Diao X, Pang X, Xie C, Guo Z, Zhong D, Chen X (2014). Bioactivation of 3-n-butylphthalide via the sulfation of its major metabolite 3-hydroxy-NBP: mediated mainly by sulfotransferase1A1. Drug Metab Dispos, 42: 774-781 14.刁星星，陈笑艳（2014）。醛氧化酶在药物代谢中的作用。宝鸡文理学院学报（自然科学版），34: 26-38。邀稿 15.Diao X, Ma Z, Wang H, Zhong D, Zhang Y, Jin J, Fan Y, Chen X (2013). Simultaneous quantitation of 3-n-butylphthalide (NBP) and its four major metabolites in human plasma by LC–MS/MS using deuterated internal standards. J Pharm Biomed Anal, 78: 19-26 16.Diao X, Ma Z, Lei P, Zhong D, Zhang Y, Chen X (2013). Enantioselective determination of 3-n-butylphthalide (NBP) in human plasma by liquid chromatography on a teicoplanin-based chiral column coupled with tandem mass spectrometry. J Chromatogr B, 939: 67-72 17.Diao X, Deng P, Xie C, Li X, Zhong D, Zhang Y, Chen X (2013). Metabolism and pharmacokinetics of 3-n-butylphthalide (NBP) in humans: the role of cytochrome P450s and alcohol dehydrogenase in biotransformation. Drug Metab Dispos, 41: 430-444